Established in 2020, OBIGEN Pharma, a subsidiary of OBI Pharma, is the first biotech startup in Taiwan specializing in the research, development, production, and manufacturing of Botulinum toxin. Their type A botulinum toxin, OBI-858, originates from an API plant adhering to the PIC/s GMP standards in the Zhubei Biomedical Science Park and a high-security sterile drug product plant in the Tainan Science Park.
Guided by diligent efforts, OBIGEN develops and produces stable quality products, contributing to advancing the entire medical industry. With a dedicated focus on innovation and vitality, OBIGEN actively forges international partnerships to globally launch the exceptional Taiwan toxin.
Company Details
- Employees
- 15
- Address
- Taipei City , Tw
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.obigenpharma.com
- Keywords
- Lincolnshire.
- HQ
- Taipei City
Obigen Pharma Questions
Obigen Pharma's website is http://www.obigenpharma.com
Obigen Pharma's LinkedIn profile is https://tw.linkedin.com/company/obigenpharma
Obigen Pharma has
15 employees.
View email and phone details for 15
employees at Obigen Pharma.
Obigen Pharma's industry is
Biotechnology Research
Obigen Pharma's top competitors are
Neova® Smartskincare,
Vetnostrum Animal Health,
Nankang Biotech Incubation Center,
Taimed Biologics,
Kerafactor Eu,
Obi Pharma,
Cenra,
Kerafactor™ Skincare For Hair,
Old Mission Aesthetics,
Buffalo Biomedical Technology Co., Ltd..
Obigen Pharma's categories are Biotechnology Research
